Infliximab in the treatment of patients with severe COVID-19 (INFLIXCOVID): protocol for a randomised, controlled, multicentre, open-label phase II clinical study.
Sina M ColdeweyCharles NeuFrank BloosPhilipp BaumbachUlrike SchumacherMichael BauerPhilipp ReukenAndreas StallmachPublished in: Trials (2022)
The trial was registered at clinicaltrials.gov ( NCT04922827 , 11 June 2021) and at EudraCT ( 2021-002098-25 , 19 May 2021).